Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2016 - 2025)

Outlook Therapeutics has reported Depreciation & Amortization (CF) over the past 8 years, most recently at $30074.0 for Q4 2025.

Quarterly Depreciation & Amortization (CF) rose 4.42% to $30074.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118325.0 through Dec 2025, up 48.35% year-over-year, with the annual reading at $117052.0 for FY2025, 2.8% up from the prior year.
Depreciation & Amortization (CF) was $30074.0 for Q4 2025 at Outlook Therapeutics, up from $29737.0 in the prior quarter.
Over five years, Depreciation & Amortization (CF) peaked at $30074.0 in Q4 2025 and troughed at $28801.0 in Q4 2024.